Faye Sharpley

1.4k total citations
33 papers, 529 citations indexed

About

Faye Sharpley is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Faye Sharpley has authored 33 papers receiving a total of 529 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 14 papers in Oncology and 13 papers in Hematology. Recurrent topics in Faye Sharpley's work include Amyloidosis: Diagnosis, Treatment, Outcomes (18 papers), Multiple Myeloma Research and Treatments (11 papers) and Cancer Treatment and Pharmacology (6 papers). Faye Sharpley is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (18 papers), Multiple Myeloma Research and Treatments (11 papers) and Cancer Treatment and Pharmacology (6 papers). Faye Sharpley collaborates with scholars based in United Kingdom, United States and Italy. Faye Sharpley's co-authors include Ashutosh Wechalekar, Shameem Mahmood, Sajitha Sachchithanantham, Helen J. Lachmann, Philip N. Hawkins, Julian D. Gillmore, Carol Whelan, Richa Manwani, Marianna Fontana and Cristina Quarta and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Faye Sharpley

28 papers receiving 518 citations

Peers

Countries citing papers authored by Faye Sharpley

Since Specialization

Citations

This map shows the geographic impact of Faye Sharpley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Faye Sharpley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Faye Sharpley more than expected).

Fields of papers citing papers by Faye Sharpley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Faye Sharpley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Faye Sharpley. The network helps show where Faye Sharpley may publish in the future.

Co-authorship network of co-authors of Faye Sharpley

This figure shows the co-authorship network connecting the top 25 collaborators of Faye Sharpley. A scholar is included among the top collaborators of Faye Sharpley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Faye Sharpley. Faye Sharpley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Frail Multiple Myeloma Patients Deserve More Than Just a Score 2023 ·SHILAP Revista de lepidopterología ·(unknown), Faye Sharpley	2
2	Is It Time for a More Holistic Approach to the Treatment of Multiple Myeloma? 2021 ·SHILAP Revista de lepidopterología ·Faye Sharpley, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
3	Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis 2020 ·British Journal of Haematology ·Oliver C. Cohen, Faye Sharpley, Julian D. Gillmore, Helen J. Lachmann, Sajitha Sachchithanantham, Shameem Mahmood, Marianna Fontana, Carol Whelan, Ana Martinez–Naharro, Charalampia Kyriakou, Neil Rabin, Rakesh Popat, Kwee Yong, (unknown), (unknown), Philip N. Hawkins, Ashutosh Wechalekar	28
4	Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients 2020 ·PLoS ONE ·(unknown), Faye Sharpley, (unknown), Grant Vallance, Toby A. Eyre, Jaimal Kothari, Sally Moore, Karthik Ramasamy	4
5	Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 2020 ·Amyloid ·Paolo Milani, Faye Sharpley, Stefan Schönland, Marco Basset, Shameem Mahmood, Mario Nuvolone, Christoph Kimmich, Andrea Foli, Sajitha Sachchithanantham, Giampaolo Merlini, Ashutosh Wechalekar, Giovanni Palladini, Ute Hegenbart	25
6	Myeloma care adaptations in the UK during SARS‐CoV‐2 pandemic: Challenges and measurable outcomes 2020 ·European Journal Of Haematology ·(unknown), Fotios Panitsas, Faye Sharpley, Alexandros Rampotas, (unknown), Sally Moore, Sarah Gooding, Jaimal Kothari, Karthik Ramasamy	2
7	The value of screening biopsies in light‐chain (AL) and transthyretin (ATTR) amyloidosis 2020 ·European Journal Of Haematology ·Oliver Cohen, Faye Sharpley, Janet A. Gilbertson, Ashutosh Wechalekar, Sajitha Sachchithanantham, Shameem Mahmood, Carol Whelan, Ana Martinez–Naharro, Marianna Fontana, Helen J. Lachmann, Philip N. Hawkins, Julian D. Gillmore	14
8	Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy 2019 ·British Journal of Haematology ·Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, Helen J. Lachmann, Julian D. Gillmore, Kwee Yong, Neil Rabin, Rakesh Popat, Charalampia Kyriakou, (unknown), Faye Sharpley, Mark Smith, (unknown), (unknown), Philip N. Hawkins, Ashutosh Wechalekar	36
9	Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era 2019 ·PLoS ONE ·Faye Sharpley, (unknown), (unknown), (unknown), Manil Subesinghe, David J. Cutter, (unknown), (unknown), (unknown), Karthik Ramasamy	12
10	Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria 2019 ·Haematologica ·Faye Sharpley, Marianna Fontana, Ana Martinez–Naharro, Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, Helen J. Lachmann, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh Wechalekar	10
11	PB2127 BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS 2019 ·HemaSphere ·(unknown), Sajitha Sachchithanantham, S. Harrison, Richa Manwani, Faye Sharpley, Candida Cristina Quarta, Tamer Rezk, (unknown), Kwee Yong, Neil Rabin, Rakesh Popat, (unknown), (unknown), (unknown), Helen J. Lachmann, CJ Whelan, JD Gillmore, (unknown), Philip N. Hawkins, (unknown)	2
12	Amyloidosis Diagnosed in Solid Organ Transplant Recipients 2019 ·Transplantation ·Faye Sharpley, Marianna Fontana, Janet A. Gilbertson, Julian D. Gillmore, Philip N. Hawkins, Shameem Mahmood, Richa Manwani, Ana Martinez–Naharro, Cristina Quarta, Tamer Rezk, Dorota Rowczenio, Sajitha Sachchithanantham, Carol Whelan, Ashutosh Wechalekar, Helen J. Lachmann	4
13	Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis 2019 ·European Journal Of Haematology ·Faye Sharpley, (unknown), Shameem Mahmood, Sajitha Sachchithanantham, Isobel Ramsay, (unknown), (unknown), Derralynn Hughes, Atul Mehta, (unknown), Paul Griffiths, Ashutosh Wechalekar	10
14	Ixazomib, lenalidomide and dexamethasone in relapsed AL amyloidosis – a first report 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Oliver C. Cohen, Faye Sharpley, Julian D. Gillmore, Helen J. Lachmann, Sajitha Sachchithanantham, Shameem Mahmood, Cristina Quarta, Marianna Fontana, Carol Whelan, Ana Martinez–Naharro, Charalampia Kyriakou, Neil Rabin, Rakesh Popat, Kwee Yong, (unknown), (unknown), Philip N. Hawkins, Ashutosh Wechalekar	0
15	Assessment of Treatment Response in Cardiac AL Amyloidosis Using CMR Mapping - Results at 3 Months, 6 Months and 1 Year Post-Chemotherapy 2018 ·UCL Discovery (University College London) ·(unknown), Tushar Kotecha, Andrea Baggiano, Michele Boldrini, Tamer Rezk, (unknown), Richa Manwani, Faye Sharpley, Sajitha Sachchithanantham, (unknown), (unknown), CJ Whelan, Helen J. Lachmann, (unknown), James Moon, Peter Kellman, JD Gillmore, Philip N. Hawkins, Marianna Fontana	1
16	Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis 2018 ·British Journal of Haematology ·Faye Sharpley, Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, Helen J. Lachmann, (unknown), Carol Whelan, Philip N. Hawkins, Ashutosh Wechalekar	12
17	A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis 2018 ·Blood ·Faye Sharpley, Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, Helen J. Lachmann, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh Wechalekar	0
18	Multiple myeloma in the very elderly patient: challenges and solutions 2016 ·Clinical Interventions in Aging ·(unknown), Toby A. Eyre, Faye Sharpley, (unknown), Karthik Ramasamy, John Willan	30
19	Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience 2016 ·Blood ·(unknown), Andrew Melville, Paul Maciocia, (unknown), Faye Sharpley, Karthik Ramasamy, Matthew Streetly, Matthew Jenner, (unknown), Stephen Schey, Rakesh Popat, Shirley D’Sa, Ali Rismani, Kwee Yong, Neil Rabin	1
20	Wolbachia Lipoprotein Stimulates Innate and Adaptive Immunity through Toll-like Receptors 2 and 6 to Induce Disease Manifestations of Filariasis 2009 ·Journal of Biological Chemistry ·Joseph D. Turner, (unknown), Kelly L. Johnston, Katrin Gentil, Louise Ford, Bo Wu, (unknown), Faye Sharpley, Barton E. Slatko, Eric Pearlman, Mark J. Taylor	107

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact